Wired News – Merck to Expand Use of Veeva Systems’ CRM in Latin America and Asia/Pacific
LONDON, UK / ACCESSWIRE / May 09, 2018 / If you want access to our free research report on Veeva Systems Inc. (NYSE: VEEV), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=VEEV as the Company's latest news hit the wire. On May 07, 2018, the Company announced that Merck & Co. (NYSE: MRK), known as MSD outside of the United States and Canada, is planning to expand its use of multichannel Veeva CRM to Latin America and Asia/Pacific. Register today and get access to over 1,000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Veeva Systems and Merck most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/?symbol=VEEV
www.active-investors.com/registration-sg/?symbol=MRK
Merck will Utilize Veeva CRM, Veeva CRM Approved Email, and Veeva CRM Events Management for All Users
Veeva Systems and Merck are building upon their seven-year partnership to help Merck standardize on a single, global CRM solution in order to drive new levels of operating efficiency and commercial effectiveness worldwide. As part of its expansion with Veeva Systems, Merck will now utilize Veeva CRM, Veeva CRM Approved Email, and Veeva CRM Events Management for all its users and markets around the globe to enable a seamless customer experience across all channels.
Moving to a Single Global CRM Solution can Help Merck be More Agile
Commenting on the announcement, Phyllis Post, Vice President and Chief Investment Officer for Global Human Health at Merck, stated that Veeva Systems has been a trusted, long-term partner of Merck. He added that moving to a single global CRM solution can help Merck be more agile while providing the foundation for delivering an efficient and personalized customer experience.
Veeva Systems Proud to Team with Merck to Bring Innovative Medicines to Market
Peter Gassner, Founder and Chief Executive Officer (CEO) of Veeva Systems, stated that the Company's ability to consistently deliver world-class cloud software helps keep its customers ahead as the life sciences industry evolves. Gassner added that Veeva Systems is proud to team with Merck on their important mission to bring innovative medicines to market.
EVER Pharma Also Adopted Veeva OpenData and Veeva CRM
On February 06, 2018, the Company announced that the specialty pharmaceutical organization, EVER Pharma, had adopted Veeva OpenData and Veeva CRM to empower its growing team in Poland with the accurate customer data necessary to drive smarter, tailored engagement with healthcare professionals (HCPs). The need for up-to-date, accurate customer data in CRM was a top priority to improve execution and ensure the success of EVER Pharma's product launches. Veeva OpenData delivered the right data in Veeva CRM for EVER Pharma to help field teams create more valued interactions with customers.
Veeva CRM Overview
Veeva CRM is the most advanced and only proven life sciences CRM solution, preferred by field teams to help them optimize customer experience. Advanced multichannel capabilities and real-time insights help engage customers in the way and channel they prefer. Informed by the industry's largest network of users, it is the latest and continually-evolving CRM solution that helps quickly adapt to changing market conditions and drive business growth. Veeva CRM is proven effective at companies of all sizes, from pre-commercial companies launching their first product to the largest global life sciences companies.
About Veeva Systems Inc.
Founded in 2007 and headquartered in Pleasanton, California, Veeva Systems is a leader in cloud-based software for the global life sciences industry. The Company's solutions enable pharmaceutical and other life sciences organizations to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance.
Stock Performance Snapshot
May 08, 2018 - At Tuesday's closing bell, Veeva Systems' stock slightly rose 0.27%, ending the trading session at $73.77.
Volume traded for the day: 667.62 thousand shares.
Stock performance in the last month – up 4.56%; previous three-month period – up 28.95%; past twelve-month period – up 33.54%; and year-to-date - up 33.45%
After yesterday's close, Veeva Systems' market cap was at $10.21 billion.
Price to Earnings (P/E) ratio was at 74.44.
The stock is part of the Technology sector, categorized under the Healthcare Information Services industry. This sector was up 0.2% at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
